Cardior: Novo Nordisk targets heart disease in $1.1 billion deal
Novo Nordisk, the Danish pharmaceutical whose market cap has swelled due to popular weight loss drugs, on Monday announced it was making an acquisition targeting cardiovascular disease.
Read full article »
Cardior is a Germany-based biopharmaceutical company that researches and develops RNA-dependent therapies for the treatment of heart diseases.
Read more